【レポートの概要（一部）】
Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Ulcerative Colitis Overview 11
Therapeutics Development 12
Pipeline Products for Ulcerative Colitis – Overview 12
Pipeline Products for Ulcerative Colitis – Comparative Analysis 13
Ulcerative Colitis – Therapeutics under Development by Companies 14
Ulcerative Colitis – Therapeutics under Investigation by Universities/Institutes 21
Ulcerative Colitis – Pipeline Products Glance 22
Late Stage Products 22
Clinical Stage Products 23
Early Stage Products 24
Unknown Stage Products 25
Ulcerative Colitis – Products under Development by Companies 26
Ulcerative Colitis – Products under Investigation by Universities/Institutes 33
Ulcerative Colitis – Companies Involved in Therapeutics Development 34
Ajinomoto Pharmaceuticals Co., Ltd. 34
AlphaMab Co., Ltd 35
Altheus Therapeutics, Inc. 36
Am-Pharma B.V. 37
Amgen Inc. 38
Astellas Pharma Inc. 39
AstraZeneca PLC 40
Athersys, Inc. 41
Atlantic Healthcare plc 42
Avaxia Biologics, Inc. 43
Biocon Limited 44
BioLineRx, Ltd. 45
Bristol-Myers Squibb Company 46
Celgene Corporation 47
Cellceutix Corporation 48
Celltrion, Inc. 49
ChemoCentryx, Inc. 50
ChironWells GmbH 51
Cosmo Pharmaceuticals S.p.A 52
Dr. Falk Pharma GmbH 53
Drais Pharmaceuticals, Inc. 54
Effimune SAS 55
Emergent BioSolutions Inc. 56
Enceladus Pharmaceuticals BV 57
Epirus Biopharmaceuticals, Inc. 58
Euroscreen S.A. 59
Farmacija d.o.o. Tuzla 60
Flexion Therapeutics, Inc. 61
Galapagos NV 62
Genentech, Inc. 63
Genfit SA 64
Genor BioPharma Co., Ltd. 65
Gilead Sciences, Inc. 66
GT Biologics Limited 67
GW Pharmaceuticals plc 68
iCo Therapeutics Inc. 69
InDex Pharmaceuticals AB 70
INOXIA Lifesciences GmbH 71
Invion Limited 72
Johnson & Johnson 73
Kaken Pharmaceutical Co., Ltd. 74
LIPID THERAPEUTICS GmbH 75
LTT Bio-Pharma Co., Ltd. 76
Mabion SA 77
Medestea Research & Production S.p.A. 78
Morphotek, Inc. 79
Nogra Pharma Limited 80
Oncobiologics, Inc. 81
Pfizer Inc. 82
Pluristem Therapeutics Inc. 83
ProtAb Ltd 84
Qu Biologics Inc. 85
Receptos, Inc. 86
Sandoz Inc. 87
Sanofi 88
Sigmoid Pharma Limited 89
Stelic Institute & Co. 90
sterna biologicals Gmbh & Co KG 91
Synergy Pharmaceuticals, Inc. 92
Takeda Pharmaceutical Company Limited 93
TiGenix NV 94
Tillotts Pharma AG 95
Trino Therapeutics Ltd 96
Vascular Biogenics Ltd. 97
Ventria Bioscience 98
Zyngenia, Inc. 99
Ulcerative Colitis – Therapeutics Assessment 100
Assessment by Monotherapy Products 100
Assessment by Combination Products 101
Assessment by Target 102
Assessment by Mechanism of Action 106
Assessment by Route of Administration 109
Assessment by Molecule Type 111
Drug Profiles 113
(mesalamine + N-acetylcysteine) – Drug Profile 113
(metenkefalin + tridecactide) – Drug Profile 115
AB-0045 – Drug Profile 116
abrilumab – Drug Profile 117
ABS-11 – Drug Profile 119
adalimumab biosimilar – Drug Profile 120
adalimumab biosimilar – Drug Profile 122
adalimumab biosimilar – Drug Profile 123
adalimumab biosimilar – Drug Profile 124
adalimumab biosimilar – Drug Profile 125
adalimumab biosimilar – Drug Profile 126
adalimumab biosimilar – Drug Profile 127
adalimumab biosimilar – Drug Profile 128
AJM-300 – Drug Profile 129
alicaforsen sodium – Drug Profile 131
Anatabine – Drug Profile 132
apremilast – Drug Profile 133
ASP-3291 – Drug Profile 136
AVX-470 – Drug Profile 137
AW/EPO-002 – Drug Profile 138
AW/EPO-003 – Drug Profile 139
AW/EPOPD-01 – Drug Profile 140
AW/EPOPD-02 – Drug Profile 141
AW/EPOPD-06 – Drug Profile 142
bertilimumab – Drug Profile 143
BL-7040 – Drug Profile 145
BLI-1006 – Drug Profile 148
brilacidin – Drug Profile 149
budesonide – Drug Profile 151
budesonide ER – Drug Profile 154
budesonide ER – Drug Profile 156
CCX-507 – Drug Profile 157
Cell Therapy for Ulcerative Colitis and Inflammatory Bowel Disease – Drug Profile 158
CNDO-201 – Drug Profile 159
Cx-602 – Drug Profile 161
cyclosporine CR – Drug Profile 162
DIMS-0150 – Drug Profile 163
Drugs for Ulcerative Colitis – Drug Profile 165
eldelumab – Drug Profile 166
enalaprilat – Drug Profile 168
ES-210 – Drug Profile 169
ESN-282 – Drug Profile 170
etrolizumab – Drug Profile 171
FX-003 – Drug Profile 173
GED-0507 – Drug Profile 174
GFT-505 – Drug Profile 175
GLPG-0974 – Drug Profile 178
GLPG-1205 – Drug Profile 179
GS-5745 – Drug Profile 180
GWP-42003 – Drug Profile 181
hyaluronate sodium – Drug Profile 183
IAC VITA – Drug Profile 184
infliximab – Drug Profile 186
infliximab biosimilar – Drug Profile 188
infliximab biosimilar – Drug Profile 190
infliximab biosimilar – Drug Profile 191
infliximab biosimilar – Drug Profile 192
INV-103 – Drug Profile 193
INV-88 – Drug Profile 195
KAG-308 – Drug Profile 196
KANAb-071 – Drug Profile 197
Leukothera – Drug Profile 198
Low Molecular Weight Heparin – Drug Profile 199
LT-0011 – Drug Profile 200
LT-02 – Drug Profile 201
MD-707 – Drug Profile 202
mesalamine – Drug Profile 203
mesalamine – Drug Profile 204
mesalamine CR – Drug Profile 205
mesalamine ER – Drug Profile 206
Monoclonal Antibodies to Antagonize Metallothioneins for Ulcerative Colitis and Crohn’s Disease – Drug Profile 208
Monoclonal Antibodies to Inhibit TNFR25 for Gastrointestinal Disorders and Asthma – Drug Profile 210
Monoclonal Antibody to Inhibit Ang-2 and TNF-a for Ulcerative Colitis, Arthritis and Inflammatory Disease – Drug Profile 211
Monoclonal Antibody to Inhibit CD3 for Autoimmune Disorders, CNS Disorders, Infectious Diseases, Liver Diseases, Metabolic Disorders and Cardiovascular Diseases – Drug Profile 212
MultiStem – Drug Profile 214
naltrexone – Drug Profile 217
Nanocort – Drug Profile 218
peficitinib – Drug Profile 220
Peptides to Inhibit IL-1 Beta for Ulcerative Colitis and Crohn’s Disease – Drug Profile 222
PF-00547659 – Drug Profile 223
PH-44 – Drug Profile 225
PH-46A – Drug Profile 226
PH-5 – Drug Profile 227
Prozumab – Drug Profile 228
QBECO – Drug Profile 229
Recombinant Human Alkaline Phosphatase – Drug Profile 231
Rosburix – Drug Profile 233
RPC-1063 – Drug Profile 234
SAR-252067 – Drug Profile 236
SB-012 – Drug Profile 237
SD-010 – Drug Profile 238
Small Molecule for Ulcerative Colitis and Inflammation – Drug Profile 239
Small Molecule to Agonize OP3 Receptor for Crohn’s Disease and Ulcerative Colitis – Drug Profile 240
Small Molecules for Gastrointestinal Disorders – Drug Profile 241
Small Molecules to Inhibit IL-13 for Ulcerative Colitis – Drug Profile 242
Small Molecules to Target IL-13 for Ulcerative Colitis – Drug Profile 243
SP-333 – Drug Profile 244
Stem Cell Therapy for Inflammatory Bowel Disease – Drug Profile 245
STNM-01 – Drug Profile 246
TAK-114 – Drug Profile 247
tofacitinib – Drug Profile 249
TP-10 – Drug Profile 253
VB-201 – Drug Profile 254
VEDA-1209 – Drug Profile 256
vedolizumab – Drug Profile 257
VEN-120 – Drug Profile 259
Ulcerative Colitis – Recent Pipeline Updates 260
Ulcerative Colitis – Dormant Projects 337
Ulcerative Colitis – Discontinued Products 340
Ulcerative Colitis – Product Development Milestones 342
Featured News & Press Releases 342
Appendix 350
Methodology 350
Coverage 350
Secondary Research 350
Primary Research 350
Expert Panel Validation 350
Contact Us 351
Disclaimer 351
【レポート販売概要】
■ タイトル：潰瘍性大腸炎(Ulcerative Colitis)の治療薬パイプライン動向（2015年上半期版）■ 英文：Ulcerative Colitis - Pipeline Review, H1 2015
■ 発行日：2015年1月22日
■ 調査会社：Global Markets Direct
■ 商品コード：GMDHC6015IDB
■ 調査対象地域：グローバル
- 院内感染(Nosocomial Infections)：世界の治験レビュー2014年下半期版Nosocomial Infections Global Clinical Trials Review, H2, 2014 Summary GlobalData's clinical trial report, “Nosocomial Infections Global Clinical Trials Review, H2, 2014" provides data on the Nosocomial Infections clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Nosocomial Infections. It includes an overview of the trial numbers and the …
- 世界のソフトウェア・デファインド・ネットワーキング(SDN)市場予測と分析(2014 – 2019)Enterprises are inclining more toward network virtualization and data center consolidation, both the trends lead to high-performance computing and complex networks. The solution offered to cater to the needs of current trend is Software-Defined Networking (SDN), an emerging approach for designing, building, and managing networks. The architecture used in SDN makes it ideal for high-bandwidth and d …
- Sodium percarbonateの世界市場Sodium percarbonate (CAS 15630-89-4) Market Research Report 2013 presents comprehensive data on Sodium percarbonate markets globally and regionally (Europe, Asia, North America etc.) The Sodium percarbonate (CAS 15630-89-4) Market Research Report 2013 includes Sodium percarbonate description, covers its application areas and related patterns. It overviews Sodium percarbonate market, names Sodium p …
- Imperial Oil Limited：石油・ガスの開発・生産動向及びコスト分析- Q1, 2013Imperial Oil Limited Oil & Gas Exploration and Production Operations and Cost Analysis - Q1, 2013 Summary Imperial Oil Limited Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comprehensive information on the operational and financial performance of the company. The report is an essential source f …
- Atripla (HIV)：市場予測と分析（～2022）Atripla (HIV) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Atripla (HIV) - Forecast and Market Analysis to 2022”. Human Immunodeficiency Virus (HIV), the causative agent of AIDS, has claimed millions of lives since its emergence. However, the advent of antiretroviral therapy (ART) has transformed the face of HIV/AIDS from a dea …
- Lipodystrophy：治療薬のグローバル治験動向（2014年上半期）Lipodystrophy Global Clinical Trials Review, H1, 2014 Summary GlobalData's clinical trial report, “Lipodystrophy Global Clinical Trials Review, H1, 2014" provides data on the Lipodystrophy clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Lipodystrophy. It includes an overview of the trial numbers and their recruitment status as per the …
- カオリン採鉱の世界市場2016-2020About Kaolin Mining Kaolin, also known as china clay or kaolinite, is a soft, white, and plastic clay. It contains fine-grained plate-like particles. It is non-abrasive, chemically inert, and has low heat and electric conductivity. The paper industry is the largest end-user of kaolin. It is used for filling and coating of paper. Kaolin is also used in many other industries such as ceramics, paints …
- たばこ製造・販売企業分析：British American Tobacco (BAT)Synopsis This report provides a unique and comprehensive analysis of the company Global, Regional and National Tobacco Players: British American Tobacco (BAT), including the corporate profile, organisation structure, financial data, and competitive positioning. The analysis also details the organisation's history, merger and acquisition activity, licensing agreements, brand portfolio, as well as a …
- 小売部門ブロックチェーンの世界市場2019-2023About this market The demand for increased online security will lead the blockchain market in the retail sector to register considerable growth in the forthcoming years. The application of blockchain for identity management helps in reducing identity and transaction fraud in offline and real-world scenarios for easy documentation and identity proofs. This will further lead the blockchain market in …
- ガラス接合用接着剤の世界市場予測：UV硬化型シアノアクリレート接着剤、シリコーン接着剤、UV硬化型エポキシ接着剤、ポリウレタン接着剤The global glass bonding adhesives market is projected to reach USD 1.76 billion by 2021 at a CAGR of 7.4%. The glass bonding adhesives market has witnessed significant growth in the recent years, and this growth is projected to persist in the coming years. Glass bonding adhesives, due to their characteristic properties such as low temperature resistance, high bond strength, excellent adhesion pro …
- 生物学的製剤API製造サービスの世界市場The biological drug API manufacturing market is estimated to grow at a CAGR of 9.0% in the first half of the forecast period. In 2017, Mammalian cell culture systems submarket represents the largest submarket within the biological drug API manufacturing industry. How this 209-page report delivers: • Provides qualitative and quantitative analysis of the leading submarkets the period 2018-2028. Visi …
- ハイブリッドクラウドの世界市場：クラウド管理・組織化、災害復旧、セキュリティ・コンプライアンス、ハイブリッドホスティングThe tremendous growth of digital services and their applications along with the growing requirements of business organizations for greater flexibility and scalability have increased the adoption rate of hybrid cloud solutions and services, thereby providing immense opportunities to the vendors. These vendors are providing advanced and scalable hybrid cloud solutions and services to various organiz …
- Strategic Oil & Gas, Ltd.：石油・ガスの開発・生産動向及びコスト分析- Q3, 2013Strategic Oil & Gas, Ltd. Oil & Gas Exploration and Production Operations and Cost Analysis - Q3, 2013 Summary Strategic Oil & Gas, Ltd. Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comprehensive information on the operational and financial performance of the company. The report is an essentia …
- モリブデンの世界市場動向2014/2015The report presents a thorough study of molybdenum, covering both global and regional markets. It aims to give a proper picture of the market, its trends, perspectives and opportunities. Comprehensive data showing molybdenum worldwide production, consumption, trade statistics and prices are provided. Each country’s market overview covers the following: molybdenum production in the country, major m …
- 微小電気機械システム（MEMS）の世界市場：タイプ別（センサー、およびアクチュエーター）、用途別（家庭用電化製品、自動車、産業、航空宇宙および防衛、ヘルスケア、およびテレコミュニケーション、その他）The micro-electromechanical systems (MEMS) technology includes very small, moving mechanical parts, and electrical components. This technology is used to fabricate sensors such as accelerometers, gyroscopes, digital compasses, inertial modules, pressure sensors, humidity sensors, and microphones. The MEMS technology holds the largest share in the overall sensor market across the globe. The impleme …
